David Gou

David Gou

Auto-generated profile, based on publicly available information

David Gou

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
DRDaniel Rayner
Daniel Rayner
JNJairo T. Nunes
Jairo T. Nunes
DGDavid Gou
David Gou
ACAlexandro W.L. Chu
Alexandro W.L. Chu
SDSi-Cheng Dai
Si-Cheng Dai
FFFarid Foroutan
Farid Foroutan
The impact of COVID-19 vaccination on clinical outcomes in solid organ transplant (SOT) recipients remains unclear. This systematic review and network meta-analysis sought to assess the efficacy and safety of COVID-19 vaccination in SOT recipients. We searched 6 databases from inception to March 1, 2024 for randomized controlled trials (RCTs) and observational studies evaluating different COVID-19 vaccination strategies in SOT recipients. Based on patient-important outcomes, we performed frequentist random-effects pairwise meta-analyses and network meta-analyses, separating RCTs and nonrandomized evidence, and used the Grading of Recommendation, Assessment, Development, and Evaluation approach to assess our certainty in the evidence. We included 6 RCTs (N = 814) and 43 observational studies (N = 125 199). Overall, there is a paucity of randomized evidence evaluating COVID-19 vaccines in SOT recipients. The nonrandomized evidence evaluating COVID-19 vaccination strategies patient-important outcomes, including COVID-19 infection, mortality, hospitalization, ICU admission, and rejection, demonstrated low to very low certainty due to the included studies' risk of bias. Throughout the COVID-19 pandemic, clinicians and SOT recipients worked with minimal, very low-quality evidence in relation to COVID-19 vaccines in this population. In the instance of future public health emergencies, clinicians and researchers should collaborate closely with patient partners to ensure there is sufficient evidence in the transplant population on patient-important outcomes.

9 December 2024 in Ophthalmology
Verified
Journal Article
Open access
BTBrendan Tao
Brendan Tao
XLXiaole Li
Xiaole Li
NCNatalie Chen
Natalie Chen
RHRyan S. Huang
Ryan S. Huang
AMAndrew Mihalache
Andrew Mihalache
RMRajeev H. Muni
Rajeev H. Muni
To compare face masking protocols for post-intravitreal injection endophthalmitis (PIE) prophylaxis. Though mask mandates are lifted, ophthalmologists may question whether continued investment into face masks will influence their PIE rate. We included comparative studies of PIE incidence by masking policy (i.e. standard care [no restrictions], no-talking, physician masking, or universal masking [patient and physician]). A frequentist network meta-analysis (Mantel-Haenszel method with fixed-effects) synthesized direct and indirect evidence. Subgroup analysis excluded studies that systematically introduced new prophylactic techniques (e.g., prefilled syringes) during the observation period. The ROBINS-I and GRADE tools evaluated risk of bias and evidence certainty. We analyzed 17 studies (2,595,219 injections, 830 events; 0.032%). For the any PIE outcome (17 studies; 2,595,219 injections), compared with standard care, PIE incidence was significantly lower with no-talking (OR: 0.56, 95%CI [0.39, 0.82], I2: 0%) and physician masking (OR: 0.72, 95%CI [0.53, 0.99], I2: 0%) policies, which remained consistent in the subgroup analysis. Although PIE rates between standard care and universal masking did not differ in the main analysis (OR: 0.83, 95%CI [0.67, 1.02]), subgroup analysis revealed a significantly lower rate of any PIE with universal masking (OR: 0.70, 95%CI [0.55, 0.91], I2: 0%) compared to standard care. For the culture-positive (14 studies; 2,347,419 injections), Streptococcus (10 studies; 1,966,903 injections), and culture-negative (15 studies; 2,213,322 injections) outcomes, PIE rates between pairs of interventions groups generally did not reach significance, likely involving limited study power. As one exception, the incidence of culture-positive PIE was significantly lower with a no-talking policy (OR: 0.45, 95%CI [0.23, 0.92], single direct estimate) compared to standard care, though this result did not persist in subgroup analysis. As well, in subgroup analysis, universal masking had a significantly lower incidence of culture-negative PIE than standard care (OR: 0.68, 95%CI [0.47, 0.98], I2: 0%). For all outcomes, by GRADE analysis, low- or very-low certainty evidence suggests that no-talking and physician masking policies may reduce culture-positive or clinical PIE rates, respectively, compared to standard care and universal masking. While data were only available for endophthalmitis, the overall comparative safety of these interventions remains unclear.

28 January 2025 in Allergy
Verified
Journal Article
Open access
DRDaniel Rayner
Daniel Rayner
DGDavid Gou
David Gou
LWLaura Weiler
Laura Weiler
LILola Irelewuyi
Lola Irelewuyi
GXGrace Xiong
Grace Xiong
TSTresha Sivanesanathan
Tresha Sivanesanathan

15 June 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
DRDaniel Rayner
Daniel Rayner
DGDavid Gou
David Gou
JLJennifer Lin
Jennifer Lin
GXGrace Xiong
Grace Xiong
AGAlessandra Giglia
Alessandra Giglia
SBShreya Bera
Shreya Bera

31 January 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
DGDavid Gou
David Gou
CKCarmen Kalo
Carmen Kalo
VGVeronica Grignano
Veronica Grignano
KGKrystal Grover
Krystal Grover
DRDaniel Rayner
Daniel Rayner

25 July 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
DRDaniel Rayner
Daniel Rayner
DGDavid Gou
David Gou
WSWayne Sun
Wayne Sun